RUA Life Sciences plc

LSE RUA.L

RUA Life Sciences plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 4.91 M

RUA Life Sciences plc Net Cash Used Provided By Financing Activities is USD 4.91 M for the year ending March 31, 2024, a 2,914.38% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

RUA Life Sciences plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 162.74 K, a 287.75% change year over year.
RUA Life Sciences plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -86.68 K, a -100.94% change year over year.
RUA Life Sciences plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 9.21 M, a 0.00% change year over year.
RUA Life Sciences plc Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 0.00, a -100.00% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

LSE: RUA.L

RUA Life Sciences plc

CEO	Mr. William Donald Brown
IPO Date	Feb. 26, 1997
Location	United Kingdom
Headquarters	2 Drummond Crescent
Employees	40
Sector	Technology
Industries 3D Printing Biotechnology Chemicals & Advanced Materials Composite Materials Hardware & Electronics Medical Instruments Plastics Robotics

Description

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.

Key trends

Past 5 years